The checkpoint molecule CD47 has high hopes riding on it in oncology as being the innate immune equivalent of PD-1. Multiple companies are developing blockers against CD47 and/or its ligand, SIRPa, for the treatment of various tumors.
Keeping you up to date on recent developments in neurology, including: Hospital improves on-time administration of medication to Parkinson patients; Scientists develop Alzheimer's drug-testing platform, discover protective gene; Blood-based biomarker can detect, predict severity of traumatic brain injury.
BioWorld looks at translational medicine, including: Base editor targets mitochondrial DNA; Everyone’s an immune cell; Brief anemia helps out nanoparticle drugs; Crosstalk between sex, stress hormones affects immunity; Astrocytes, endocannabinoids, metabolism cooperate to affect behavior; CDK-like kinase plays role in sensing pain; RNA editing restores Rett protein; Single-cell studies give insights into pulmonary fibrosis.
Keeping you up to date on recent developments in diagnostics, including: Diagnosing fatty liver disease; Assessing COVID-19 with lung ultrasound; Noncoding mutations contribute to heart disease.
Exercise is a powerful way to keep the elderly brain working well, not just in individuals that are healthy, but also in those with neurodegenerative disease. Even individuals with familial Alzheimer’s, though they will develop dementia regardless of whether they exercise or not, will have relatively better cognitive function if they exercise than if they don’t.
Keeping you up to date on recent developments in orthopedics, including: Buzzing to rebuild broken bone; Tiny mineral particles are better vehicles for promising gene therapy; New trial results question standard treatment plan for rheumatoid arthritis.
Forty years after HIV became a global pandemic, there are now more than 30 drugs approved to treat it. The National Institute of Allergy and Infectious Diseases’ director, Anthony Fauci, and clinical director, Clifford Lane, opined in the July 2, 2020, issue of The New England Journal of Medicine that “considering the spectacular scientific advances that have been made over nearly four decades, it is conceivable that with optimal implementation of available prevention strategies and treatments, the end of HIV/AIDS as a global pandemic will be attainable.”
A large epidemiological study published in the July 6, 2020, advance online issue of The Lancet found that most individuals who became infected with SARS-CoV-2 developed antibodies to the virus, confirming that infection usually results in at least a short-term immune response.
Keeping you up to date on recent developments in oncology, including: Researchers float ChIA PET as answer to prostate cancer puzzle; Dana-Farber offers liquid biopsy for renal cell carcinoma; Inhaled indocyanine green may enable lung tumor margin depiction.
A large epidemiological study published in the July 6, 2020, advance online issue of The Lancet found that most individuals who became infected with SARS-CoV-2 developed antibodies to the virus, confirming that infection usually results in at least a short-term immune response.
RSS
